NVO Crashes 21% in a Month: Is This an Indication to Sell the Stock?

Key Takeaways NVO shares plunged 20.5% in a month after issuing weaker-than-expected 2026 guidance.Novo Nordisk expects 2026 sales and operating profit to decline 5-13% at CER on an adjusted basis.Intensifying competition, U.S. pricing pressure and slowing prescriptions weigh on semaglutide growth.Novo Nordisk (NVO) shares have plunged 20.5% in the past month. The massive sell-off of the stock was primarily driven by a weaker-than-expected 2026 financial outlook issued by the company, despite its fourth-qua ...